Clinical trial / 2009
Yamabushitake (Hericium erinaceus) supplementation significantly improved cognitive function scores in adults with mild cognitive impairment.
Thirty Japanese men and women aged 50 to 80 with mild cognitive impairment were randomized to take either Yamabushitake (four 250 mg tablets containing 96% dry powder three times daily) or placebo for 16 weeks, followed by 4 weeks of observation. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased cognitive function scale scores compared with placebo, with scores increasing with duration of intake. However, scores decreased significantly by 4 weeks after terminating intake. Laboratory tests showed no adverse effects.
- Study type
- Double-blind, parallel-group, placebo-controlled randomized trial
- Who was studied
- 30 Japanese men and women aged 50 to 80 years diagnosed with mild cognitive impairment
- What was measured
- Cognitive function scores based on the Revised Hasegawa Dementia Scale (HDS-R) and adverse effects
THE PAPER
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.
Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Phytother Res, 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.